Psychiatric diagnosis

McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant to Develop a Digital Therapy for Major Depression Disorder with Anhedonia Symptoms

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Psychiatric diagnosis, Medical specialties, Articles, Harvard Medical School, McLean Hospital, National Register of Historic Places in Cambridge, Massachusetts, Scott L. Rauch, BIRD Foundation, Post-traumatic stress disorder, Digital therapeutics, Major depressive disorder

HAIFA, Israel, July 29, 2021 /PRNewswire/ -- GrayMatters Health , a digital therapeutics start-up company, announced that the BIRD Israel-U.S. Binational Industrial Research and Development Foundation awarded a grant to McLean Hospital and the company to develop a novel solution for the therapy of Major Depression Disorder (MDD).

Key Points: 
  • HAIFA, Israel, July 29, 2021 /PRNewswire/ -- GrayMatters Health , a digital therapeutics start-up company, announced that the BIRD Israel-U.S. Binational Industrial Research and Development Foundation awarded a grant to McLean Hospital and the company to develop a novel solution for the therapy of Major Depression Disorder (MDD).
  • "We are excited about this collaboration with GrayMatters Health and we are grateful to the BIRD Foundation for their support that will allow McLean and GrayMatters Health to advance our work together to develop innovative approaches to effectively treat depression," said Scott L. Rauch, MD, McLean president and psychiatrist-in-chief commented.
  • Oded Kraft, co-founder and CEO of GrayMatters concluded, "This project will enable us to expand our indications from PTSD to depression.
  • GrayMatters Health Ltd., based in Haifa, Israel, is developing innovative neuroscience-based digital therapeutics for mental health disorders.

Global Lyme Alliance Funds Groundbreaking Study Linking Lyme Disease to Psychiatric Disorders

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Medicine, Mind, Psychiatric diagnosis, Abnormal psychology, Neuropsychology, Medical terminology, Borderline personality disorder, Suicidal ideation, Tick-Borne Disease Alliance, Differential diagnoses of depression, Lyme disease

It has long been suspected that Lyme disease may increase the risk of psychiatric disorders, including depression and suicidal ideation.

Key Points: 
  • It has long been suspected that Lyme disease may increase the risk of psychiatric disorders, including depression and suicidal ideation.
  • This study found that with a single diagnosis of Lyme disease, there is a 24% increased risk of any mental disorder, including depression.
  • Moreover, people with Lyme disease have a two-fold higher risk75% higherof dying by suicide than those without Lyme disease.
  • Global Lyme Alliance (GLA) is the leading 501(c)(3) dedicated to conquering Lyme disease through research, education, and patient services.

Timberline Knolls Offers Advice for Coping with Eating Disorder Symptoms During Summer

Retrieved on: 
Wednesday, July 28, 2021
Abnormal psychology, Psychiatry, Eating disorders, Psychology, Psychiatric diagnosis, Mind, Behavioral neuroscience, Binge eating disorder, Emotional eating

However, for those struggling with an eating disorder , the summer months can present new challenges in managing symptoms and maintaining recovery.

Key Points: 
  • However, for those struggling with an eating disorder , the summer months can present new challenges in managing symptoms and maintaining recovery.
  • Body image concerns are one of the main reasons why summer may be a difficult time for individuals in eating disorder recovery.
  • Here are some tips for coping with eating disorder symptoms during the summer:
    The summer can be a difficult time for those in eating disorder recovery.
  • We are also on Facebook Timberline Knolls , LinkedIn Timberline Knolls and Twitter @TimberlineToday.

New research reveals most Americans can’t identify the symptoms of depression

Retrieved on: 
Wednesday, July 28, 2021
Psychiatry, Psychiatric diagnosis, Branches of biology, Psychology, Pharmacogenomics, Attention deficit hyperactivity disorder, Mental disorder, Major depressive disorder, Management of depression, Anxiety

For a better understanding of potential symptoms of depression and to experience how hard it can be to go about daily life while living with depression, visit KnowMentalHealth.com .

Key Points: 
  • For a better understanding of potential symptoms of depression and to experience how hard it can be to go about daily life while living with depression, visit KnowMentalHealth.com .
  • For more information on how genetic testing can help inform clinicians on depression treatment, please visit GeneSight.com .
  • The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.
  • The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 61 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions.

Autism Science Foundation Funds Four New ‘Baby Siblings Research Consortium’ Grants

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Abnormal psychology, Psychiatry, Autism, Psychiatric diagnosis, Pervasive developmental disorders, Autism Science Foundation, Autism Speaks, Autism rights movement

New York, July 28, 2021 (GLOBE NEWSWIRE) -- The Autism Science Foundation (ASF), a not-for-profit organization dedicated to supporting and funding innovative autism research, today announced its 2021 Baby Siblings Research Consortium (BSRC) database grant recipients.

Key Points: 
  • New York, July 28, 2021 (GLOBE NEWSWIRE) -- The Autism Science Foundation (ASF), a not-for-profit organization dedicated to supporting and funding innovative autism research, today announced its 2021 Baby Siblings Research Consortium (BSRC) database grant recipients.
  • Its mission is to support autism research by providing funding to scientists and organizations conducting autism research.
  • ASF also provides information about autism to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism.
  • To learn more about the Autism Science Foundation or to make a donation, visit www.autismsciencefoundation.org.

Katherine Bonincontri is recognized by Continental Who's Who

Retrieved on: 
Wednesday, July 28, 2021
Psychiatry, Psychiatric diagnosis, Addiction, Substance dependence, Substance use disorder, Mental health, Health, Medical specialties

CROFTON, Md., July 28, 2021 /PRNewswire/ --Katherine Bonincontri is being recognized by Continental Who's Who as a Trusted Executive in the field of Behavioral and Mental Health Services and for her outstanding contributions as President & Executive Director at Robert A. Pascal Youth & Family Services.

Key Points: 
  • CROFTON, Md., July 28, 2021 /PRNewswire/ --Katherine Bonincontri is being recognized by Continental Who's Who as a Trusted Executive in the field of Behavioral and Mental Health Services and for her outstanding contributions as President & Executive Director at Robert A. Pascal Youth & Family Services.
  • Throughout her distinguished career, Mrs. Katherine Bonincontri has made a great impact in her community, fueled by her passion for caring for people and their psychological wellbeing.
  • In her current capacity, Mrs. Bonincontri provides innovative treatments to individuals with behavioral health and substance abuse disorders.
  • Mrs. Bonincontri dedicates this honorable recognition with special thanks to my husband of seven years, Phillip Bonincontri.

Researchers from The Fenway Institute, MGH, and Stanford University find that early social transition for transgender youth results in good mental health outcomes

Retrieved on: 
Wednesday, July 28, 2021
Personal life, Articles, Adolescence, Puberty, Transgender, LGBT, Gender identity, Suicide, Psychiatric diagnosis, Transphobia, Healthcare and the LGBT community

There were no associations between social transition during childhood and adverse mental health outcomes when compared with social transition during adulthood.

Key Points: 
  • There were no associations between social transition during childhood and adverse mental health outcomes when compared with social transition during adulthood.
  • Social transition during adolescence initially seemed to be associated with greater odds of some measures of suicidality compared with social transition during adulthood.
  • "These results strongly suggest that social transition itself will not harm transgender and gender diverse youth.
  • "Timing of Social Transition for Transgender and Gender Diverse Youth, K-12 Harassment, and Adult Mental Health Outcomes" is available online here .

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Clinical medicine, Sedatives, Psychiatric diagnosis, Addiction, Addiction medicine, Cognitive behavioral therapy, Ketamine, Major depressive disorder, Behaviour therapy, Suicide

The funding will be used to evaluate the effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy (iCBT), to rapidly reduce suicidality in persons with depression, when compared to iCBT alone.

Key Points: 
  • The funding will be used to evaluate the effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy (iCBT), to rapidly reduce suicidality in persons with depression, when compared to iCBT alone.
  • It is separately reported in the biomedical literature that cognitive behavioural therapy may also reduce suicidality, but requires several weeks to months before reductions in suicidality are significant.
  • "Integrating ketamine with CBT provides an opportunity to rapidly reduce suicidality and sustain the effect over the long term.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Protein O-GlcNAcase, Neurological disorders, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Dementia

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Protein O-GlcNAcase, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Tau protein

LAUSANNE, Switzerland and SAN FRANSICO, July 28, 2021 /PRNewswire/ -- Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer's Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.
  • The Peter Davies Memorial Symposium: The Future of Tau Based Therapies (preclinical, early phase, current studies, future)